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ABSTRACT
 Benzimidazole derivatives are known to represent a class of medicinally important compounds 
which are extensively used in drug design and catalysis. A series of 2-substituted benzimidazole 
derivatives 10a-i was herein synthesized from the reaction of o-phenylenediamine with some 
amino acids using ameliorable pathway. The chemical structures of the synthesized compounds 
were confirmed by IR, UV, 1H-NMR, 13C-NMR, Mass spectral and analytical data. The compounds 
were investigated for their antimicrobial activity alongside gentamicin clinical standard. The results 
showed that this skeletal framework exhibited marked potency as antimicrobial agents. The most 
active compound was 1H-benzo[d]imidazol-2-yl)methanamine, 10a. 
 Key words: antibacterial activity, benzimidazole, SAR study,
spectral data,bioactive heterocycle.
INTRODUCTION
 Over the years, the heterocyclic compounds 
have attracted numerous attentions due to their 
wide applications in medicinal chemistry research1. 
Nitrogen-containing heterocyclic compounds 
have been prominent even in early studies of 
chemistry. Benzimidazole is a benzo-fused 
imidazole which constitutes an important class 
of heterocyclic compound in numerous natural 
and synthetic compounds in medicinal chemistry 
for new drug development2. The most prominent 
benzimidazole compound in nature is N-ribosyl-
dimethylbenzimidazole, which serves as an axial 
ligand for cobalt in vitamin B12 core3. Diverse 
synthetic efforts for benzimidazoles have been 
110 AJANI et al., Orient. J. Chem.,  Vol. 32(1), 109-120 (2016)
reported, with the most common method being 
the heterocyclization of o-phenylenediamine and 
carboxylic acids2, aldehydes4, alcohols5 and nitriles6. 
This usually require strong acid, high temperature, 
and sometimes photo-irradiation conditions, 
precious metal salts7, molecular oxygen8, or 2,3-
dichloro-5,6-dicyano-1,4-benzoquinone as oxidant9. 
Iridium-catalyzed acceptor-less dehydrogenative 
coupling of tertiary amines was recently reported as 
novel strategy for the synthesis of benzimidazole10. 
Benzimidazole derivatives are present in numerous 
valuable bioactive compounds and are marketed as 
commercial drugs useful in human and veterinary 
medicines some of which are as shown in Fig. 1 as 
benzimidazole-based drugs1–9.
 Fur thermore, benzimidazole moiety 
is a crucial template in medicinal chemistry 
because of its wide variety of reported biological 
and pharmacological activities, some of which 
include anticancer11, antimicrobial12, antitumor13, 
antimalarial14,anti-HIV15, anti-inflammatory16, 
antitubercular17, anthelmintic18, anticonvulsant19, 
antioxidant20, anti-ulcer21, anti-HBV22, among 
others. The pharmacological investigation showed 
that the antagonism of Ang II-induced pressure 
response by oral administration of a series of 
benzimidazole hybrid was obviously superior to that 
of clinical drug standard used. This result suggested 
that NO-releasing benzimidazole hybrids may 
provide a promising approach for the discovery of 
Fig. 1: Pharmaceutically important and commonly marketed benzimidazole-based drugs
novel antihypertensive agents23. Benzimidazole 
derivatives were recently reviewed as target 
agents for antidiabetic by different mechanisms 
such as peroxisome proliferator–activated receptor 
á-transcriptional activity, glycosidases receptor, 
dipeptidyl peptidase IV, glucokinase, human 
glucagon receptor (hGCGR) antagonist, aldose 
reductase enzyme and stearoyl-CoA desaturase24. 
Benzimidazole and its derivatives are reported to 
be physiologically and pharmacologically active 
and some applications are found in the treatment 
of several diseases including epilepsy, diabetes 
and infertility25. A targeted benzimidazole motif was 
reported by Chu et al. (2015) to potently induced 
apoptosis via the c-Jun N-terminal kinase (JNK)-
mediated death receptor 5 up-regulation in breast 
cancer cells26. 
 In similar manner, amino acid are utilized 
in living cells for protein synthesis under the control 
of genes are in a special category since they are 
fundamental to all life forms as building blocks 
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for peptides and proteins27. Hence, we envisage 
that incorporation of amino acid moieties in the 
benzimidazole scaffold may lead to formation of 
biologically relevant compounds essential in the 
future drug discovery.
EXPERIMENTAL
 All chemical compounds and reagents 
used were obtained from Sigma-Aldrich Chemicals 
and BDH Chemical Companies, but were made 
available by Department of Chemistry, Covenant 
University. Solvents used were of analytical grade 
and were used directly without further purification. 
Melting points of the compounds were determined 
in open capillary tubes on Stuart melting point 
apparatus and were uncorrected. The IR spectra 
were run in solid state using the Bruker FT-IR 
while UV spectrophotometric analyses of all the 
samples were run in ethanol, using UV-Genesys 
spectrophotometer. The 1H-NMR and 13C-NMR of the 
compounds were run on Bruker NMR machine at 400 
MHz and 100 MHz respectively. The chemical shifts 
were measured with reference to tetramethylsilane 
(TMS) as internal standard and the solvent used 
was deuteriated DMSO. The elemental analysis (C, 
H, N) of compounds were performed using a Carlo 
Erba-1108 elemental analyzer. Results were found 
to be in good agreement with the calculated values 
(Table 2). The pH was monitored using Portable pH 
Meter Model PHB4. All drying were conducted at 
reduced pressure with DHG-9023A Vacuum Oven. 
In addition, column chromatographic purifications 
were carried out on the products, where necessary, 
using CHCl3/CH3OH (9:1) solvent system and Merck 
silica gel F (Mesh 200-300). Organic solutions were 
dried over anhydrous Na2SO4 and concentrated with 
a RE-2000B Buchi Rotary Evaporator at reduced 
pressure. The progress of the reaction and the level 
of purity of the compounds were routinely checked 
by TLC on silica gel plates using different solvent 
system based on the variation of polarity of the 
product of interest and the developed plates were 
visualized under UV light. 
General procedure for synthesis of 
2-substitutedbenzimidazole derivatives, 
10a-i Method A
 o-Phenylenediamine (0.54 g, 5 mmol) 
and required amino acid or athranilic acid (7 mmol) 
were put in a round bottom flask and stirred in 
20 ml of ethanol at room temperature until the 
mixture showed some level of solubility. Afterward, 
the mixture was refluxed for about 5 minutes and 
solution of concentrated hydrochloric acid and 
water (1:1 ! 1.0 ml) was added to the mixture. White 
fume was observed on addition of the solution. The 
reflux continued for 9 h under carefully controlled 
temperature of 85 – 95 oC until reaction was 
completed (TLC monitored). The product was 
neutralized with 40% NH4OH and concentrated to 
one-third of its original volume and left in the freezer 
overnight for proper crystallization. The solution 
was then filtered by suction to afford (1H-benzo[d]
imidazol-2-yl)methanamine, 10a in 68.1% yield. 
Method B
 o-Phenylenediamine (0.54 g, 5 mmol) and 
required amino acid or anthranilic acid (7 mmol) was 
added sequentially to 10 ml of toluene in a quickfit 
flask. The reacting mixture was heated under reflux 
at carefully controlled temperature of 85 – 95 oC 
for 9 h under the influence of a magnetic stirrer 
to obtain coloured solution which was allowed to 
cool overnight. The crystals formed was filtered 
and air-dried to afford (1H-benzo[d]imidazol-2-yl)
methanamine, 10a in 97.3% yield. Due to high 
efficiency observed in Method B for the synthesis of 
10a, it was therefore adopted as the viable method 
for the synthesis of the rest of the compounds 
10b-i. 
Synthesis of (1H-benzo[d]imidazol-2-yl) 
methanamine, 10a
 Treatment of o-phenylenediamine (0.54 g, 
5 mmol) with L-glycine (0.53 g, 7 mmol) afforded 
(1H-benzo[d]imidazol-2-yl)methanamine, 10a. 1H-
NMR (400 MHz, DMSO-d6) δ: 7.95 (s, 1H, NH), 
7.82-7.80 (d, J = 8.03 Hz, 2H, Ar-H), 7.17-7.13 (m, 
2H, Ar-H), 6.44-6.42 (t, J = 5.78 Hz, 2H, NH2-CH2), 
3.55-3.53 (t, J = 5.78 Hz, 2H, CH2-NH2). 13C-NMR 
(100 MHz, DMSO-d6) δ: 142.6, 139.3, 138.9, 125.3, 
125.3, 119.2, 119.2, 41.7 ppm. l
max 
in nm (log ε
max
): 
236 (1.7782), 290 (1.324), 407 (0.8541). IR (KBr): 
3384, 3363 (N-H of NH2, two bands), 3245 (N-H), 
3021 (C-H aromatic), 2930 (C-H aliphatic), 1605 
(C=C), 1580 (C=N), 741 (Ar-H) cm-1. MS: in m/z (rel. 
%): 295.04 (2M + 1, 10.5%), 148.01 (MH, 24.5%), 
147.03 (M+, 20%), 132.04 (M – NH, 100%), 118.07 
(M – CH2=NH, 35.3%), 76.11 (68.3%).
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Synthesis of 1-(1H-benzo[d]imidazol-2-yl)-2-
methylpropan-1-amine, 10b
 Treatment of o-phenylenediamine (0.54 g, 5 
mmol) and L-valine (0.82 g, 7 mmol) afforded 1-(1H-
benzo[d]imidazol-2-yl)-2-methylpropan-1-amine, 
10b. 1H-NMR (400 MHz, DMSO-d6) δ: 8.01 (s, 1H, 
NH), 7.67-7.65 (d, J = 8.00 Hz, 2H, Ar-H), 7.11-7.07 
(m, 2H, Ar-H), 6.23-6.21 (d, J = 6.28 Hz, 2H, NH2-
CH), 2.73-2.69 (dt, J1 = 4.34 Hz, J1 = 6.28 Hz, 1H, 
CH-CH2-NH2), 1.68 (m, 1H, CH-CH-(CH3)2), 0.99 (d, 
J = 4.34 Hz, 3H, CH3-CH), 0.93 (d, J = 4.35 Hz, 3H, 
CH3-CH). 13C-NMR (100 MHz, DMSO-d6) δ: 143.1, 
138.2, 138.1, 125.7, 125.7, 118.5, 118.5, 44.7 (CH), 
38.9 (CH), 18.7 (2 × CH3) ppm. lmax in nm (log εmax): 
209 (3.3653), 236 (2.893), 293 (2.5185). IR (KBr): 
3384, 3363 (N-H of NH2, two bands), 3117 (N-H), 
2962 (C-H aliphatic of CH3), 1603 (C=C aromatic), 
1591 (C=N), 775 (Ar-H) cm-1. MS: in m/z (rel. %): 
189.15 (M+, 100%), 174.13 (M – NH, 66.3%), 147.16 
(M – CH(CH3)2), 132.12 (34.2%), 106.11 (23.4%), 
76.14 (44.3%).
Synthesis of 4-amino-4-(1H-benzo[d]imidazol-2-
yl)butanamide (10c)
 Treatment of o-phenylenediamine (0.54 g, 
5 mmol) with L-glutamine (1.02 g, 7 mmol) afforded 
4-amino-4-(1H-benzo[d]imidazol-2-yl)butanamide, 
10c. 1H-NMR (400 MHz, DMSO-d6) δ: 11.21 (s, 2H, 
NH2–C=O), 8.27 (s, 1H, NH), 7.53-7.51 (d, J = 8.00 
Hz, 2H, Ar-H), 7.19-7.15 (m, 2H, Ar-H), 6.29-6.27 
(d, J = 6.51 Hz, 2H, NH2-CH), 4.11-4.10 (t, J = 4.35 
Hz, 1H, CH-CH2), 2.94-2.92 (t, J = 7.85 Hz, 2H, 
CH2-CH2), 2.77-2.74 (m, 2H, CH2). 13C-NMR (100 
MHz, DMSO-d6) d: 178.3 (C=O), 145.3, 139.2, 139.1, 
126.5, 126.5, 119.2, 119.2, 55.8 (CH), 34.6 (CH2), 
34.1 (CH2) ppm. lmax in nm (log εmax): 209 (3.2842), 
236 (3.1562), 293 (2.3054). IR (KBr): 3384, 3364 
(N-H of NH2, two bands), 3235 (N-H), 3200 (N-H), 
2927 (C-H aliphatic of CH2), 2803 (C-H aliphatic), 
1685 (C=O of amide), 1605 (C=C aromatic), 
1575 (C=N), 748 (Ar-H) cm-1. MS: in m/z (rel. %): 
245.11 (48.1%), 236.14 (M + H2O, 100%), 218.15 
(M+, 65.7%), 175.14 (M – CONH, 22.4%), 147.14 
(45.7%). 
Synthesis of 2-(pyrrolidin-2-yl)-1H-benzo[d]
imidazole, 10d
 Treatment of o-phenylenediamine (0.54 
g, 5 mmol) with L-proline (0.81 g, 7 mmol) afforded 
2-(pyrrolidin-2-yl)-1H-benzo[d]imidazole, 10d. 1H-
NMR (400 MHz, DMSO-d6) δ: 8.21 (s, 1H, NH), 7.61-
7.59 (d, J = 8.00 Hz, 2H, Ar-H), 7.13-7.10 (m, 2H, 
Ar-H), 5.98-5.96 (m, 1H, NH of pyrrolo-), 3.98-3.97 (t, 
J = 4.91 Hz, 1H, CH-CH2), 2.87-2.85 (t, J = 7.23 Hz, 
2H, CH2-CH2), 2.09-2.05 (m, 2H, CH2), 1.94-1.90 (m, 
2H, CH2). 13C-NMR (100 MHz, DMSO-d6) δ: 144.9, 
139.6, 139.5, 127.2, 127.2, 118.9, 118.9, 61.8 (CH), 
45.33 (CH2), 36.5 (CH2), 25.7 (CH2). lmax in nm (log 
ε
max
): 209 (3.3520), 239 (2.6522), 293 (2.2810). IR 
(KBr): 3322 (N-H), 3124 (N-H aliphatic), 3027 (C-H 
aromatic), 2928 (C-H aliphatic of CH2), 2857 (C-H 
aliphatic), 1600 (C=C aromatic), 1577 (C=N), 744 
(Ar-H) cm-1. MS: in m/z (rel. %): 204.13 (67.5%), 
187.15 (M+, 100%), 119.14 (73.32%), 106.13 (100%), 
77.04 (32.11%).
Synthesis of 4-(2-amino-2-(1H-benzo[d]imidazol-
2-yl)ethyl)phenol, 10e
 Treatment of o-phenylenediamine (0.54 g, 5 
mmol) with L-tyrosine (1.27 g, 7 mmol) afforded 4-(2-
amino-2-(1H-benzo[d]imidazol-2-yl)ethyl)phenol, 
10e. 1H-NMR (400 MHz, DMSO-d6) δ: 8.21 (s, 1H, 
NH), 7.69-7.67 (d, J = 8.26 Hz, 2H, Ar-H of OTs), 
7.59-7.57 (m, 2H, Ar-H), 7.03-7.01 (d, J = 8.40 Hz, 
2H, Ar-H of benzyl), 6.85-6.83 (d, J = 8.40 Hz, 2H, 
Ar-H of benzyl), 5.14-5.12 (d, J = 8.50 Hz, 1H, NH2-
CH), 4.17-4.12 (m, 1H, NH2-CH-CH2), 3.11-3.06 (dd, 
J1 = 5.20 Hz, J2 = 20.00 Hz, 1H, CH of CH2-Ar), 2.97-
2.92 (dd, J1 = 6.80 Hz, J2 = 20.00 Hz, 1H, CH of CH2-
Ar). l
max 
in nm (log ε
max
): 209 (3.3677), 236 (2.796), 
293 (2.4698). IR (KBr): 3384, 3363 (N-H of NH2, two 
bands), 3200 (N-H), 3117 (O-H, broad), 2929 (C-H 
aliphatic of CH2), 2876, 2827 (C-H aliphatic), 1600 
(C=C aromatic), 1584 (C=N), 739 (Ar-H) cm-1. MS: 
in m/z (rel. %): 253.17 (M+, 96.7%), 236.13 (M – OH, 
77.2%), 221.16 (M – NHOH, 82.3%), 187.15 (58.1%), 
119.14 (73.32%), 106.13 (100%), 77.14 (19.3%).
                                               
Synthesis of 1-(1H-benzo[d]imidazol-2-yl)-2-
phenylethanamine, 10f
 Treatment of o-phenylenediamine (0.54 g, 5 
mmol) with L-phenylalanine (1.16 g, 7 mmol) afforded 
1-(1H-benzo [d]imidazol-2-yl)-2-phenylethanamine, 
10f. 1H-NMR (400 MHz, DMSO-d6) δ: 8.23 (s, 1H, 
NH), 7.63-7.61 (d, J = 8.26 Hz, 2H, Ar-H), 7.57-7.55 
(m, 2H, Ar-H), 7.24-7.21 (m, 5H, Ar-H of benzyl), 
5.14-5.12 (d, J = 8.45 Hz, 1H, NH2-CH), 4.22-4.17 
(m, 1H, CH), 3.12-3.08 (dd, J1 = 5.60 Hz, J2 = 20 
Hz, 1H), 3.03-2.98 (dd, J1 = 6.40 Hz, J2 = 20 Hz, 
1H). 13C-NMR (100 MHz, DMSO-d6) δ: 143.9, 136.6, 
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134.9, 129.8 (2CH aromatic), 129.6 (2CH aromatic), 
128.8 (2CH aromatic), 127.5, 127.2 (2CH aromatic), 
119.5, 56.5, 39.0 (CH2), 21.7 (CH3). lmax in nm (log 
ε
max
): 212 (3.4050), 236 (2.9974), 293 (2.6857). IR 
(KBr): 3384, 3363 (N-H of NH2, two bands), 3209 
(N-H), 3022 (C=H aromatic), 2889 (C-H aliphatic), 
1615 (C=C aromatic), 1575 (C=N), 749 (Ar-H) cm-1. 
MS: in m/z (rel. %): 237.09 (M+, 94.5%), 236.08 (M – 
H, 67.9%), 217.11 (58.4%), 187.15 (58.1%), 119.14 
(73.7%), 106.09 (100%), 77.12 (40.7%).
                                                     
Synthesis of 1-(1H-benzo[d]imidazol-2-yl)-3-
(methylthio)propan-1-amine, 10g
 Treatment of o-phenylenediamine (0.54 g, 
5 mmol) with L-methionine (1.04 g, 7 mmol) afforded 
1-(1H-benzo [d]imidazol-2-yl)-3-(methylthio)propan-
1-amine, 10g. 1H-NMR (400 MHz, DMSO-d6) d: 
8.23 (s, 1H, NH), 7.75-7.73 (d, J = 8 Hz, 2H, Ar-H), 
7.29-7.27 (m, 2H, Ar-H), 5.68-5.66 (d, J = 7.55 Hz, 
2H, NH2-CH), 2.50-2.48 (m, 1H, CH), 2.35-2.33 (t, 
J = 8.88 Hz, 2H, CH2-CH2-S), 1.97 (s, 3H, CH3-S), 
1.82-1.73 (m, 2H, CH-CH2-CH2). 13C-NMR (100 MHz, 
DMSO-d6) δ: 145.3, 139.3, 139.1, 126.9, 126.9, 
117.3, 117.3, 58.2 (CH), 43.7 (CH2), 31.2 (CH2), 
15.9 (CH3). lmax in nm (log εmax): 209 (3.3181), 236 
(2.6064), 293 (2.2553). IR (KBr): 3384, 3363 (N-H 
of NH2, two bands), 3276 (N-H), 3173 (N-H), 3029 
(C-H aromatic), 2921 (C-H aliphatic of CH2), 2885 
(C-H aliphatic), 1600 (C=C), 1575 (C=N), 745 (Ar-H) 
cm-1. MS: in m/z (rel. %): 221.08 (M+, 75.9%), 195.07 
(51.7%), 182.07 (82.5%), 164.07 (M – SCH3, 89.3%), 
106.09 (100%), 77.12 (40.7%).
Synthesis of 1-(1H-benzo[d]imidazol-2-yl)
pentane-1,5-diamine, 10h
 Treatment of o-phenylenediamine (0.54 
g, 5 mmol) with L-lysine (1.28 g, 7 mmol) afforded 
1-(1H-benzo[d]imidazol-2-yl)pentane-1,5-diamine, 
10h. 1H-NMR (400 MHz, DMSO-d6) δ: 8.51 (s, 1H, 
NH), 7.78-7.76 (d, J = 8 Hz, 2H, Ar-H), 7.37-7.34 
(m, 2H, Ar-H), 6.23-6.21 (d, J = 7.75 Hz, 2H, NH2-
CH), 5.97-5.94 (t, J = 8.04 Hz, 2H, NH2-CH2), 3.91-
3.94 (m, 1H, CH), 2.35-2.33 (t, J = 8.04 Hz, 2H, 
CH2-CH2-NH2), 2.13-2.11 (quintet, J = 8.17 Hz, 2H, 
CH2-CH2-CH2), 1.92-1.90 (quintet, J = 8.14 Hz, 2H, 
CH2-CH2-CH2), 1.82-1.73 (m, 2H, CH-CH2-CH2). 13C-
NMR (100 MHz, DMSO-d6) δ: 145.3, 139.6, 139.4, 
126.7, 126.7, 119.9, 119.9, 55.8, 43.1, 39.6, 32.9, 
21.5 ppm. l
max 
in nm (log ε
max
): 206 (2.6222), 236 
(1.5911), 296 (0.6021). IR (KBr): 3383, 3365 (N-H 
of NH2, two bands), 3276 (N-H), 3173 (N-H), 3026 
(C-H aromatic), 2929 (C-H aliphatic of CH2), 2845 
(C-H aliphatic), 1603 (C=C aromatic), 1583 (C=N), 
742 (Ar-H) cm-1. MS: in m/z (rel. %): 218.17 (M+, 
89.3%), 190.17 (M – N2, 100%), 162.16 (73.5%), 
145.03 (41.6%), 106.15 (96.2%), 77.17 (40.7%).
Synthesis of 2-(1H-benzo[d]imidazol-2-yl)aniline, 
10i
 Treatment of o-phenylenediamine (0.54 g, 5 
mmol) with anthranilic acid (0.96 g, 7 mmol) afforded 
2-(1H-benzo [d]imidazol-2-yl)aniline, 10i. 1H-NMR 
(400 MHz, DMSO-d6) δ: 11.13 (s, 2H, NH2), 8.49 
(s, 1H, NH), 7.96-7.94 (d, J = 8.08 Hz, 2H, Ar-H), 
7.78-7.76 (d, J = 8.00 Hz, 2H, Ar-H), 7.37-7.34 (m, 
2H, Ar-H), 6.87-6.85 (m, 2H, Ar-H). 13C-NMR (100 
MHz, DMSO-d6) d: 147.4, 143.2, 139.5, 139.3, 139.1, 
128.1, 128.0, 126.7, 126.5, 119.8, 119.7, 119.3, 
119.2 ppm. l
max 
in nm (log ε
max
): 209 (3.1553),  242 
(2.4914), 335 (2.0899). IR (KBr): 3384, 3366 (N-H of 
NH2, two bands), 3201 (N-H), 3031 (C-H aromatic), 
1576 (C=N), 748 (Ar-H) cm-1. MS: in m/z (rel. %): 
209.23 (M+, 76.5%), 194.25 (M – NH, 91.4%), 118. 
22 (44.24%), 106.15 (100%), 77.25 (38.2%).
                                              
Antimicrobial Activity
 The antimicrobial proper ties of the 
2-substituted benzimidazole derivatives were 
investigated in form of the general sensitivity 
testing with respect to six targeted organisms. 
The six organisms of interest in this present study 
are Staphylococcus aureus, Proteus vulgaris, 
Streptococcus faecalis, Klebsiella pneumonia, 
Pseudomonas aeruginosa and Escherichia coli 
which pose serious threat to life of man and animals 
from time to time. They are associated with the 
gastrointestinal tract damage in man and animal. 
Antibacterial Sensitivity Testing of Compounds
 All the synthesized benzimidazole templates 
and gentamicin were screened for antibacterial 
activity on the targeted organisms mentioned above 
using agar well diffusion method29. The medium 
employed was diagnostic sensitivity test agar 
(Biotech Ltd). With the aid of a sterile 1 mL pipette, 
about 0.2 mL of the broth culture of test organism 
was added to 18 mL sterile molten diagnostic 
sensitivity test agar (Biotech Ltd) which had already 
cooled down to 45 oC. This was well mixed and 
poured into previously sterilized petri dishes, which 
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had been properly labeled according to the test 
organisms. The medium was then allowed to set. With 
the aid of a sterile cork borer, the required numbers 
of holes were bored into the medium. The wells were 
made of about 5 mm to the edge of the plate. The 
wells were then filled up aseptically with the solution 
of the compound in DMSO using Pasteur pipettes. 
Gentamicin was used as the standard antibacterial 
agent at a concentration of 1000 µg/mL. The plates 
were allowed to stand for about 1 h on the bench 
for proper diffusion of the antibacterial agents into 
the medium and then incubated uprightly at 37 oC 
for 24 h. Care was taken not to stockpile the plates. 
Clear zones of inhibition (Z.O.I.) in millimeters (mm) 
indicated the relative susceptibility of the bacteria to 
the compounds and Gentamicin clinical reference.
RESULTS AND DISCUSSION
 In the continuation of our effort on the 
synthesis of substituted benzimidazole as viable 
heterocyclic compounds for the possible antimicrobial 
evaluation2, we have herein reported synthesis of 
alkanamino substituted benzimidazole. Generally, 
as far as synthesis is concerned, the alkanamino-
benzimidazole derivatives 10a-h were obtained in 
83.3 – 97.3% yields by the direct [4+1]-cycloaddition 
of various amino acids with o-phenylenediamine and 
the pathway is as shown in Scheme 1. In a similar 
manner, when the condensation was carried out 
using anthranilic acid as the lone pair acceptor with 
sp2 hybridized carbon, 2-(1H-benzo[d]imidazol-2-yl)
aniline, 10i was obtained in 83.4% yield. In detail, 
Table 1: Comparative study of catalyzed and non-catalyzed synthesis of 10a 
Entry Solvent Catalyst Temperature oC Time h Yield %
Method A Ethanol HCl / H2O 85 – 95 9 68.1
Method B Toluene No catalyst 85 – 95 9 97.1
Method A: Catalyzed synthetic approach using HCl:H2O (1:1). Method B: Non-catalyzed but solvent 
dependent synthetic approach in toluene.
Scheme 1: Synthesis of alkanamido benzimidazole derivatives, 10a-i 
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preliminary optimization of reaction conditions was 
done by comparing the synthesis of 10a under two 
different Methods. Method A involves the refluxing 
of ethanolic solution of o-phenylenediamine 
with glycine in HCl/H2O (1:1 → 1.0 ml) medium 
as described in our previous work2. The newly 
established method herein involves the synthesis 
in non-catalyzed medium but with toluene solvent 
(Method B). Firstly, the thermodynamic evaluation 
was carried out to establish the optimum temperature 
of the reaction condition which was found to be 
between 85 and 95 oC. This temperature was then 
used as the refluxing temperature for both methods 
and the result was as shown in Table 1. It was 
discovered that the catalyzed Method A afforded 
product 10a in 68.1% yield while toluene solvent 
dependent Method B afforded 10a in 97.3% yield 
(Table 1). Since the Method B produced the 10a in 
higher yield, it was therefore adopted as the synthetic 
route for the preparation of all other benzimidazoles 
10b-i. Hence, from the reaction optimization study, 
the synthesis of 2-substituted benzimidazoles 10a-i 
was successfully achieved in high yields (83.3 – 
97.3%) by heating the mixture under reflux at a 
carefully controlled temperature of 85 – 95 oC for 
9 h in the presence of toluene solvent . In addition, 
having obtained these targeted benzimidazole 
derivatives 10a-i, the physico-chemical analyses 
were carried out and the result is as shown in Table 
2. The molecular weight of the compounds varied 
between 147.18 for 10a and 238.28 for 10e. The 
melting points of all the compounds were above 
200 oC which might be as a result of the formation of 
imino functionality of benzimidazole and possibility 
of intramolecular hydrogen bonding phenomenon. 
Four of the compounds (10a, 10c, 10d and 10i) 
were brown in colour while the rest (10b, 10e, 10f, 
10g and 10h) were cream coloured crystalline 
solids. The spectroscopic characterization of the 
synthesized compounds was carried out using 
UV-Visible, FT-IR, 1H-NMR and 13C-NMR as well 
as mass spectral data. The results of the electronic 
transition using uv spectroscopy was investigated 
in ethanol solution and the result is as presented in 
the experimental section showing the wavelength 
(l
max
) and the log of molar absorptivity (Log ε
max
). 
The UV–visible spectrum of 10a, as representative 
sample, gave rise to wavelength (l
max
) at 236 nm, 
290 nm and 407 nm with log ε
max
 values of 1.78, 
1.32 and 0.85, respectively. The wavelength at 
236 nm was as a result of occurrence of p→p* 
transition of C=C confirming the presence of 
benzenoid ring which was in agreement with 
earlier established value by Ajani et al. (2013)2. 
The wavelength at 290 nm was as a result of p→n 
transition which may be ascribed to the auxochromic 
C=N group; characteristic of K bands of C=N 
functional group28. A bathochromic shift observed 
at wavelength of 407 nm was due to the presence 
of extensive conjugation, auxochromic character of 
lone pair on nitrogen in position-1 and chromophoric 
nature of the benzimidazole ring itself. The infrared 
analysis was carried out using Bruker Fourier-
Transform Infrared (FT-IR) and the various absorption 
bands from stretching and bending vibrational 
frequencies were duly reported. For instance, the 
IR spectrum of 10a exhibited the absorption bands 
at 3384 cm-1 and 3363 cm-1 due to the presence of 
N-H stretching vibration of primary amine (NH2) while 
the band at 3245 cm-1 depicted the presence of N-H 
of secondary amine in the heterocyclic ring portion 
of 10a (i.e. NH of imidazole ring). The stretching 
frequency of C-H aromatic was found at 3021 cm-1 
which was further confirmed with the Ar-H bending 
frequency at 741 cm-1. The C-H stretching vibrational 
frequency of aliphatic (CH2) was observed at 2930 
cm-1 while the bands at 1605 cm-1 and 1580 cm-1 
depicted the presence of C=C aromatic and C=N 
imino functionalities respectively. 
 Furthermore, the 1H-NMR and 13C-NMR 
of the compounds were run in either DMSO-d6 or 
CDCl3 depending on the solubility of the particular 
compound. A proton singlet at d 7.95 ppm was 
due to presence of NH of imidazole portion while 
four aromatic protons were noticed as two proton 
doublets at d 7.82–7.80 ppm with coupling constant 
of 8.03 Hz and the remaining two aromatic protons 
as a multipet at d 7.17–7.13 ppm. The NH2 linked 
to methylene group (CH2) of 10a appeared as a 
two protons triplet at d 6.44–6.42 ppm while its two 
neighbouring protons of appeared as a triplet at d 
3.55–3.53 ppm. The neighbouring effect of the NH2 
and CH2 on each other was confirmed by the fact 
that they both have the same coupling constant of 
5.78 Hz. The result of the 13C-NMR of 10a was run at 
100 MHz using deuterated DMSO-d6 as the solvent. 
It showed the presence of eight carbon atoms with 
the d
c
 ranging from 142.6 ppm to 41.7 ppm. These 
eight carbon atoms of 10a was made up of seven 
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aromatic carbon atoms (142.6–119.2 ppm) and one 
aliphatic carbon atom of CH2 at 41.7 ppm. The mass 
spectrum of 10a showed the molecular ion peak 
at m/z 147.03 with relative intensity of 20%. It is 
interesting to note that this peak correlated well with 
molecular weight of 10a. The base peak which was 
observed at m/z 132.04 and with relative intensity 
of 100% was as a result of loss of NH (i.e. M – NH). 
Other daughter fragments observed at m/z 295.04, 
148.01, 118.07 and 76.11 with relative intensities of 
10.5%, 24.5%, 35.3% and 68.3% respectively were 
as a result of some fragmentation processes. The 
result of elemental analysis did not only correlate 
well with the molecular masses of all compounds 
but also showed a consistent minimum difference of 
not more than ±0.25 between % calculated and % 
found for the carbon, hydrogen and nitrogen atoms 
of compound 10a as well as other compounds 
(Table 2).
Antibacterial activities 
 The antibacterial activity of nine synthesized 
compounds, 10a-i, was determined in vitro by agar 
well diffusion technique as described by Russell 
and Fur (1977)29. The media were inoculated 
with test organisms and a solution of the tested 
compound in DMSO solvent. The zones of inhibition 
were measured after 24 h of incubation. The in 
vitro general sensitivity testing of the prepared 
compounds was carried out against three gram 
positive bacteria (Staphylococcus aureus, Proteus 
vulgaris and Streptococcus faecalis) and three 
gram negative bacteria (Klebsiella pneumonia, 
Pseudomonas aeruginosa and Escherichia coli). 
Result of antibacterial screening (sensitivity testing) 
on bacteria with zones of inhibition duly recorded in 
millimetre (mm) is shown in Table 3. The choice of 
use of gentamicin as clinical standards is based on 
the fact that at low concentrations, gentamicin only 
inhibits growth of the bacteria through induction 
of prokaryotic ribosomes to misread mRNA30. 
Gentamicin also prevents initiation of protein 
synthesis and leads to death of microbial cells. Also 
in humans, they have structurally different ribosomes 
from bacteria, thereby allowing the selectivity of 
this antibiotic for bacteria. Gentamicin inhibits 
Table 2: Results of the physico-chemical parameters of the synthesized compounds 
Comp Molecular Molecular Melting Yield Sample  Elemental Analysis Data
No Formula Weight Pt. (oC)  (%) Colour   %Calcd. (%Found)
      C H N
10a C8H9N3 147.18 > 200 97.3 brown 65.29 6.16 28.55
      (65.31) (6.18) (28.52)
10b C12H16N2 188.27 > 200 85.1 cream 76.55 8.57 14.88
      (76.52) (8.59) (14.91)
10c C12H15N3O 217.27 > 200 84.3 brown 66.34 6.96 19.34
      (66.38) (7.21) (19.16)
10d C11H13N3 187.24 >200 89.0 brown 70.56 7.00 22.44
      (70.71) (6.84) (22.61)
10e C12H15N3O 238.28 > 200 83.3 cream 75.61 5.92 11.76
      (75.79) (6.11) (11.81)
10f C15H15N3 237.30 > 200 84.0 cream 75.92 6.37 17.71
      (75.88) (6.21) (17.69)
10g C11H14N2S 206.31 > 200 97.1 cream 64.04 6.84 13.58
      (63.97) (6.95) (13.76)
10h C12H17N3 203.28 > 200 88.2 cream 70.90 8.43 20.67
      (70.79) (8.40) (20.55)
10i C13H11N3 209.25 > 200 83.4 brown 74.62 5.30 20.08
      (74.81) (5.43) (19.98)
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bacterial growth by inhibiting protein biosynthesis. Its 
mechanism of action is similar to that of streptomycin 
and other aminoglycoside antibiotics. 
 From the result of sensitivity testing, 
probable activities of these benzimidazoles family 
on the tested organisms were categorized based on 
the size of zone of inhibition (Table 3). Interestingly, 
it was observed that majority of the compounds 
exhibited probable and highly promising significant 
activities based on the large zone of inhibition 
reported. In fact, many of these benzimidazole 
derivatives had larger zones of inhibition against all 
the six organisms when compared with gentamicin 
standard. Generally speaking, compounds 10f 
showed the largest zone of inhibition of 42 ± 0.10 
mm against Klebsiella pneumonia while 10g had 
the least zone of inhibition of 19 ± 0.10 mm against 
Proteus vulgaris among all the screened compounds. 
Compounds 10c and 10h had similar activity of all 
the tested organisms since they displayed similarity 
in the size of zones of inhibition ranging from 28 ± 
Table 3: Result of in vitro antibacterial screening on bacteria with zones of inhibition (mm)
Organism→ Staphylococcus Proteus Streptococcus Klebsiella Pseudomonas Escherichia
 aureus vulgaris  faecalis pneumonia aeruginosa coli
Comp No ↓ 
  
10a 38 ± 0.20 35 ± 0.10 38 ± 0.20 40 ± 0.13 30 ± 0.10 40 ± 0.20
10b 35 ± 0.10 30 ± 0.20 32 ± 0.20 35 ± 0.10 20 ± 0.10 40 ± 0.10
10c 30 ± 0.10 28 ± 0.20 30 ± 0.10 35 ± 0.10 32 ± 0.13 35 ± 0.10
10d 38 ± 0.10 20 ± 0.10 35 ± 0.10 40 ± 0.20 35 ± 0.20 35 ± 0.13
10e 34 ± 0.20 20 ± 0.11 30 ± 0.10 36 ± 0.10 36 ± 0.20 32 ± 0.20
10f 32 ± 0.20 30 ± 0.10 30 ± 0.10 42 ± 0.10 32 ± 0.14 34 ± 0.10
10g 24 ± 0.10 19 ± 0.10 32 ± 0.20 36 ± 0.12 30 ± 0.10 34 ± 0.10
10h 28 ± 0.20 30 ± 0.14 35 ± 0.14 32 ± 0.20 30 ± 0.13 30 ± 0.11
10i 36 ± 0.10 30 ± 0.20 36 ± 0.10 36 ± 0.14 30 ± 0.29 36 ± 0.10
Gent 10 ± 0.10 18 ± 0.10 15 ± 0.20 07 ± 0.20 12 ± 0.14 04 ± 0.20
amicin Staphylococcus aureus (G+), Proteus vulgaris (G+), Streptococcus faecalis (G+), Klebsiella 
pneumonia (G-), Pseudomonas aeruginosa (G-), Escherichia coli (G-). G+ = Gram positive, G- = Gram 
negative. Mean ± Standard deviation of triplicate measurement. 
Fig. 2: The result of selectivity index of synthesized compounds using S. aureus (G+ organism)
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Fig. 3: The result of selectivity index of synthesized compounds using E. coli (G- organism)
0.20 mm to 35 ± 0.10 mm. This similarity in activity 
of these two compounds could be traceable to the 
fact that both 10c and 10h had two NH2 functional 
groups. Larger zones of inhibition were experienced 
upon the screening of all compounds against S. 
aureus, except 10h with Z.O.I. of 24 ± 0.10 mm 
which was an indication that the presence of long 
aliphatic chain length and thiomethyl group projected 
an antagonistic effect on the potency of 10h. The 
result of screening unveiled 10a (Z.O.I. = 35 ± 0.10 
mm) to be most active while 10g (Z.O.I. = 19 ± 0.10 
mm) was the least active against Proteus vulgaris 
and also being almost similar to that of gentamicin 
antibiotic (Z.O.I. = 18 ± 0.10 mm). The screening on 
third gram positive organism, Streptococcus faecalis, 
showed 10a (Z.O.I. = 38 ± 0.20 mm) to be most active 
while 10c, 10e, 10f (Z.O.I. = 30 ± 0.10 mm) which 
were the least active were even two fold more active 
than gentamicin antibiotic (Z.O.I. = 15 ± 0.20 mm) in 
the inhibition of the growth of Streptococcus faecalis. 
Considering the response  of three gram negative 
organisms to compounds 10a-i, it was discovered 
that the efficacy was so high with the Z.O.I. ≥ 30 ± 
0.10 mm except for 10b (Z.O.I. = 20 ± 0.10 mm) 
against the growth of Pseudomonas aeruginosa. 
Thus, from morphological feature, the synthesized 
benzimidazoles 10a-i had better potency on the 
gram negative than the gram positive bacterial 
isolates. The morphological evidence suggests that 
the initial binding of the antibiotic disrupts the packing 
order of lipopolysaccharide of the outer membrane, 
which ultimately forms holes in the cell envelope and 
could have led to cell lysis. This was in agreement 
with the finding of Kadurugamuwa et al. (1993) who 
revealed that gentamicin has two potentially lethal 
effects on gram-negative cells31, which might have 
originated from inhibition of protein synthesis and 
surface perturbation; the two effects in concerted 
nature make aminoglycoside drugs particularly 
effective antibiotics.
 Furthermore, the comparative study of 
selectivity index therein was evaluated by using 
one gram positive (Staphylococcus aureus) and 
one gram negative (Escherichia coli) organisms. 
From this result, it was obvious that activity of the 
targeted compounds on E. coli is stronger than 
that of the Staphylococcus aureus throughout the 
screened range. It was also interesting to note that 
the benzimidazoles 10a-i were more active than the 
clinical standard gentamicin since all of them have 
higher selectivity indices than gentamicin. The result 
of the selectivity index of the synthesized compounds 
with respect to gentamicin on S. aureus and E. coli 
are as shown in Fig 2 and Fig. 3 respectively. Against 
the gram negative representative E. coli, compounds 
10a and 10b were ten times more active than the 
gentamicin standard against the growth of the gram 
negative E. coli. This showed that short length side 
chain alkyl group led to an improved activity since 
10a with methylene side chain exhibited highest 
activity against E. coli growth. Also, compound 10e 
(R = OH) with S.I. = 8.00, was less active than  10f 
(R = H) with S.I. value of 8.50. Although, 10e and 
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10f were structurally related but for the nature of 
substituent on para position of their phenyl ring. 
Hence, it could be deduced that the presence of 
electron donating group (OH) on para position of 
phenyl ring led to reduction in the activity against 
E. coli., it is herein suggested that the presence of 
amino functionality in all the synthesized compounds 
contributed synergistic effect in their improved 
antimicrobial efficiencies, just like in aminoglycoside 
antibiotics. Based on the report from the in vitro 
screening and selectivity index result, the potency of 
the compounds 10a H” 10d > 10i > 10b > 10e > 10f 
> 10c > 10h > 10g > gentamicin regarding inhibition 
of the growth of S. aureus (the representative of 
the gram positive organisms). In a like manner, the 
potency of the compounds 10a H” 10b > 10i > 10c 
H” 10d > 10f H” 10g > 10e > 10h > gentamicin 
regarding inhibition of the growth of E. coli (the 
representative of the gram negative organisms). 
The amalgamation of two or more heterocyclic 
cores has drawn substantial attention in medicinal 
chemistry. Hence, combination of amino acid with 
o-phenylenediamine in the formation of 2-substituted 
benzimidazole heterocyclic cores have, in no 
doubt, led to increase in the structural complexity 
of designed molecules which made them to exhibit 
and display better biological properties on all the 
organisms as compared with gentamicin clinical 
standard.
 
CONCLUSION
 The synthesis of new 2-substituted 
benzimidazole derivatives 10a-i was herein 
successfully achieved in improved yields via 
solvent dependent approach in toluene. Most of the 
tested compounds were found to be significantly 
effective against all the three gram positive 
bacteria (Staphylococcus aureus, Proteus vulgaris 
and Streptococcus faecalis) and the three gram-
negative bacterial strains (Klebsiella pneumoniae, 
Pseudomonas aeruginosa and Escherichia coli), 
among which compounds 10a, 10b, 10f and 10i 
surfaced out as the most effective antibacterial 
agents which are some folds more active than the 
standard gentamicin. Thus, this work will be very 
useful for further studies in terms of MIC test, toxicity 
effect and Structural Activity Relationship (SAR) 
to improve their biological and pharmacological 
properties for future drug development.
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